NEW YORK (GenomeWeb) – Roche today reported that its 2017 diagnostics revenues grew 5 percent year over year, driven by strength in immunodiagnostic product sales within its centralized and point-of-care solutions business.

For the year ended Dec. 31, Roche's Diagnostics division reported revenues of CHF 12.08 billion ($12.93 billion), up from CHF 11.47 billion in the prior year. The diagnostics division reported fourth quarter revenues of CHF 3.28 billion, up 4 percent from CHF 3.11 billion in Q4 2016.